Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
The Strategic vs the Scientific MSL
Summary
In this episode, Tom Caravela is joined by Joy Morrell to explore the multifaceted role of Medical Science Liaisons (MSLs) in medical affairs. They discuss the critical importance of dialogue over monologue in MSL communication, emphasizing the need for both scientific expertise and soft skills development. Joy highlights the significance of active listening and posing key questions to enhance engagement. The conversation shifts to MSLs as strategic advisers and the importance of ongoing training for excellence. They share insights on cultivating a high-performance MSL team and offer tips for strategic growth, while also considering the future impact of AI on the profession. The episode concludes with final advice for aspiring MSLs and leaders.
Key Points
- MSLs must transition from merely sharing scientific data to providing strategic value by understanding and addressing broader healthcare ecosystem challenges. Active listening and engaging in meaningful dialogue with stakeholders are crucial skills that MSLs need to cultivate to be more effective. Organizations should focus on developing MSLs' human skills, such as emotional intelligence and strategic thinking, through intentional training and mentorship.
Medical Science Liaisons, MSL communication, strategic advisers, soft skills development, active listening, healthcare ecosystem challenges, AI impact on MSLs
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary